Kintor Pharma IPO: Valuation Insights
Kintor Pharmaceutical (9939 HK) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers and...
460 Views
Kintor Pharma (å¼ęčÆäø) IPO: Weak in Cornerstone but Still Expect Upside
Kintor Pharma launched book building today to raise up to USD 240 million to listing in Hong Kong. Book will be closed swiftly on Friday. In our...
627 Views
ECM Weekly (10 May 2020) - Kingsoft Cloud, NetEase, Central China New Life, Peijia Medical, Kintor,
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. As...
607 Views
Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
400 Views
Kintor Pharma (å¼ęčÆäø) Pre-IPO: Post Hearing Updates and Efficacy of Reference Products
Kintor was founded by Chinese academic researchers returning from overseas. It has two main drugs, proxalutamide which targets prostate cancer and...
572 Views